Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия dvoretski@mail.ru
Список исп. литературыСкрыть список 1. World Health Organization. Evidence-informed policy-making. 2016. URL: http: //www.who.int/evidence 2. Хроническая обструктивная болезнь легких. Клинические рекомендации Минздрава России. М., 2023. Chronic obstructive pulmonary disease. Clinical recommendations. Ministry of Health of Russia. Moscow, 2023 (in Russian). 3. Лазебник Л.Б., Конев Ю.В. Исторические особенности и семантические трудности использования терминов, обозначающих множественность заболеваний у одного больного. Экспериментальная и клиническая гастроэнтерология. 2018; 154 (6): 4–9. Lazebnik LB, Konev YuV. Historical features and semantic difficulties of using terms denoting the multiplicity of diseases in one patient. Experimental and clinical gastroenterology. 2018; 154 (6): 4–9 (in Russian). 4. Feinstein AR. The pre-therapeutic classification of comorbidity in chronic disease. J Chronic Diseases. 1970; 23 (7): 455–68. 5. GOLD-2023. URL: https://erj.ersjournals.com/content/early/2023/ 02/23/13993003.00239-2023 6. Putcha N, Drummond MB, Wise RA, Hansel NN. Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management. Semin Respir Crit Care Med. 2015; 36 (4): 575–91. DOI: 10.1055/s-0035-1556063 7. Raherison C, Ouaalaya E-H, Bernady A et al. Comorbidities and COPD severity in a clinic-based cohort. BMC Pulm Med. 2018; 18 (1): 117. DOI: 10.1186/s12890-018-0684-7 8. Верткин А.Л. Коморбидный пациент. М., 2015. Vertkin A.L. Comorbid patient. Moscow, 2015 (in Russian). 9. Vanfleteren LE, Spruit MA, Groenen M et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187 (7): 728–35. DOI: 10.1164/rccm.201209-1665OC. PMID: 23392440 10. Верткин А.Л., Скотинков А.С., Тихоновская Е.Ю. и др. Коморбидность при ХОБЛ. Роль хронического воспаления. Русский медицинский журнал. 2014; (11): 811–94. Vertkin AL, Skotnikov AS, Tikhonovskaya EYu et al. Comorbidity in COPD. The role of chronic inflammation. Russ Med J. 2014; (11): 811–94 (in Russian). 11. Schunemann HJ, Dorn J, Grant BJ. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the. Buffalo Health Study. Chest. 2000; 118: 656–64. 12. Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev. 2018; 27 (149): 180057. DOI: 10.1183/16000617.0057-2018 13. Anthonisen NR, Connett JE, Enright PL, Manfreda J; Lung Health Study Research Group. Hospitalizations and mor-tality in the Lung Health Study. Am J Respir Crit Care Med. 2002; 166 (3): 333–9. DOI: 10.1164/rccm.2110093 14. Papaporfyriou A, Bartziokas K, Gompelmann D et al. Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy. Life (Basel). 2023; 13 (6): 1299. DOI: 10.3390/life13061299 15. Kotlyarov S. Analysis of the Comorbid Course of Chronic Obstructive Pulmonary Disease. J Pers Med. 2023; 13 (7): 1179. DOI: 10.3390/jpm13071179 16. Rehab A Mohammed, Layla A Mohamed, Eman M Abdelsalam et al. Assessment of Cardiac Dysfunction in Patients With Chronic Obstructive Pulmonary Disease (COPD): A Cross-Sectional Study Cureus. 2023; 15 (5): e39629. DOI: 10.7759/cureus.39629 17. Sin DD, Man SF. Why Are Patients With Chronic Obstructive Pulmonary Disease at Increased Risk of Cardiovascular Diseases? The Potential Role of Systemic Inflammation in Chronic Obstructive Pulmonary Disease. Circulation. 2003; 107: 1514–9. DOI: 10.1161/01.CIR.0000056767.69054.B3 18. Graat-Verboom L, van den Borne BE, Smeenk FW et al. Osteoporosis in COPD outpatients based on bone mineral density and vertebral fractures. J Bone Miner Res. 2011; 26 (3): 561–8. 19. Chen Y et al Prevalence and risk factors for osteoporosis in individuals with COPD: a systematic review and meta‐analysis. Chest. 2019; 156 (6): 1092–110. 20. Bitar AN, Syed Sulaiman SA, Ali IAH et al. Osteoporosis among patients with chronic obstructive pulmonary disease: systematic review and meta‐analysis of prevalence, severity, and therapeutic outcomes. J Pharm Bioallied Sci. 2019; 11 (4): 310–20. 21. Баранова И.А., Сулейманова А.К. Остеопороз и низкоэнергетические переломы у пациентов пульмонологического профиля: фокус на хроническую обструктивную болезнь легких. Эффективная фармакотерапия. 2020; 16 (19): 52–7. Baranova IA, Suleymanova AK. Osteoporosis and low-energy fractures in patients with pulmonological profile: focus on chronic obstructive pulmonary disease. Effective pharmacotherapy. 2020; 16 (19): 52–7 (in Russian). 22. Jaramillo JD, Wilson C, Stinson DS et al. Reduced bone density and vertebral fractures in smokers. Men and COPD patients at increased risk. Ann Am Thorac Soc. 2015; 12 (5): 648–56. 23. Morden NE, Sullivan SD, Bartle B, Lee TA. Skeletal health in men with chronic lung disease: rates of testing, treatment, and fractures. Osteoporos Int. 2011; 22 (6): 1855–62. 24. Graat-Verboom L, Smeenk FW, van den Borne BE et al. Progression of osteoporosis in patients with COPD: a 3-year follow up study. Respir Med. 2012; 106 (6): 861–70. 25. Bon J, Fuhrman CR, Weissfeld JL et al. Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med. 2011; 183 (7): 885–90. DOI: 10.1164/rccm.201004-0666OC 26. Romme EA, Murchison JT, Edwards LD et al. CT-measured bone attenuation in patients with chronic obstructive pulmonary disease: relation to clinical features and outcomes. J Bone Miner Res. 2013; 28 (6): 1369–77. 27. Yujuan Li, Hongchang Gao, Lei Zhao, Jinrui Wang. Osteoporosis in COPD patients: Risk factors and pulmonary rehabilitation. Clin Respirator J. 2022; 17 (10): 837. DOI: 10.1111/crj.13514 28. Attaran D, Khajedalouee M, Ahmadi F et al. Anemia in COPD patients and its relation to serum levels of erythro poietin. Tanaffos 2009; 8 (2): 11–6. 29. Fidan A, Tokmak M, Kiral N et al. Anemia in COPD and related factors. Chest. 2010; 138: 457A. 30. Ergan B, Ergün R. Impact of anemia on short-term survival in severe COPD exacerbations: a cohort study. Int J Chronic Obstructive Pulmonary Disease. 2016; 11 (1): 1775–83. 31. Lomholt FK, Laulund AS, Bjarnason NH et al. Meta-analysis of routine blood tests as predictors of mortality in COPD. Eur Clin Respir J. 2014; (1): 24110. DOI: 10.3402/ecrj.v1.24110 32. John M, Lange A, Hoernig S et al. Prevalence of anemia in chronic obstructive pulmonary disease: comparison to other chronic diseases. Int J Cardiol. 2006; 111: 365–70. 33. Krishnan G, Grant BJ, Muti PC et al. Association between anemia and quality of life in a population sample of individuals with chronic obstructive pulmonary disease. BMC Pulm Med. 2006; 6: 23. 34. Chambellan A, Chailleux E, Similowski T; the ANTADIR observatory group. Prognostic value of the hematocrit in patients with severe COPD receiving longterm oxygen therapy. Chest 2005; 128: 1201–8. 35. Celli BR, Cote CG, Marin JM et al. The bodymass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350: 1005–12. 36. Kim J, Lee J, Kim Y et al. Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: a national cross-sectional cohort study. BMC Pulmonary Medicine. 2013, 13: 51. URL: http: //www.biomedcentral.com/1471-2466/13/51 37. Takada K, Matsumoto S, Kojima E et al. Prospective evaluation of the relationship between acute exacerbations of COPD and gastroesophageal reflux disease diagnosed by questionnaire. Respir Med. 2011; 105 (10): 1531–6. 38. Rascon-Aguilar IE, Pamer M, Wludyka P et al. Role of gastroesophageal reflux symptoms in exacerbations of COPD. Chest 2006; 130 (4): 1096–101. 39. Rogha M, Behravesh B, Pourmoghaddas Z: Association of gastresophageal reflux disease symptoms with exacerbations of chronic obstructive pulmonary disease. J Gastrointestin Liver Dis. 2010; 19 (3): 253–6. 40. García Rodríguez LA, Ruigómez A, Martín-Merino E et al. Relationship between gastroesophageal reflux disease and COPD in UK primary care. Chest. 2008; 134 (6): 1223–30. DOI: 10.1378/chest.08-0902 41. Wang X, Wright Z, Wang J et al. Elucidating the Link: Chronic Obstructive Pulmonary Disease and the Complex Interplay of Gastroesophageal Reflux Disease and Reflux-Related Complications. Medicina. 2023; 59: 1270. DOI: 10.3390/medicina59071270 42. Lee AL, Button BM, Denehy L et al. Proximal and distal gastro-oesophageal reflux in chronic obstructive pulmonary disease and bronchiectasis. Respirology. 2014; 19 (2): 211–7. DOI: 10.1111/resp.12182 43. Timms C, Thomas PS, Yates DH. Detection of gastro-oesophageal reflux disease (GORD) in patients with obstructive lung disease using exhaled breath profiling. J Breath Res. 2012; 6 (1): 016003. DOI: 10.1088/1752-7155/6/1/016003 44. Sakae TM, Pizzichini MM, Teixeira PJ et al. Exacerbations of COPD and symptoms of gastroesophageal reflux: a systematic review and meta-analysis. J Bras Pneumol. 2013; 39 (3): 259–71. DOI: 10.1590/S1806-37132013000300002 45. Hafiz M, Yunus F, Suryamin M et al. Prevalence and Risk Factors of GERD among Stable COPD Patients. J Respir. 2023; 9: 1–6. 46. Eliasson G, Janson Ch, Johansson G et al. Comorbid conditions as predictors of mortality in severe COPD – an eight-year follow-up cohort study. Eur Clin Respirator J. 2023; 10 (1): 2181291. DOI: 10.1080/20018525.2023.2181291 47. Gaddam S, Gunukula SK, Lohr JW, Arora P. Prevalence of chronic kidney disease in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMC Pulm Med. 2016; 16 (1): 158. DOI: 10.1186/s12890-016-0315-0 48. AbdelHalim HA, AboElNaga HH. Is Renal Impairment an Anticipated COPD Comorbidity? Respir Care. 2016; 61 (9): 1201–6. DOI: 10.4187/respcare.04516 49. Park B, Park M, Chang J, Kim S et al. Chronic obstructive pulmonary disease and metabolic syndrome: A nationwide survey in Korea. Int J Tuberc Lung Dis. 2012; 16: 694–700. DOI: 10.5588/ijtld.11.0180 50. Lin WY, Yao CA, Wang HC et al. Impaired lung function is associated with obesity and metabolic syndrome in adults. Obesity (Silver Spring). 2006; 14: 1654–61. 51. Будневский А.В., Овсянников Е.С., Лабжания Н.Б. Сочетание хронической обструктивной болезни легких и метаболического синдрома: патофизиологические и клинические особенности. Терапевтический архив. 2017; 89 (1): 123–7. Budnevsky AV, Ovsyannikov ES, Labzhania NB. Combination of chronic obstructive pulmonary disease and metabolic syndrome: pathophysiological and clinical features. Therapeutic Archive. 2017; 89 (1): 123–7 (in Russian). 52. Воронкова О.В., Саприна Т.В., Букреева Е.Б., Зима А.П. Этиопатогенетические параллели и нерешенные вопросы патогенеза коморбидности хронической обструктивной болезни легких и метаболического синдрома (обзор литерауры). Ожирение и метаболизм. 2020; 17 (30): 292. Voronkova OV, Saprina TV, Bukreeva EB, Zima AP. Etiopathogenetic parallels and unresolved issues of the pathogenesis of comorbidity of chronic obstructive pulmonary disease and metabolic syndrome (literature review). Obesity and Metabolism. 2020; 17 (30): 292 (in Russian). 53. Baniya S. Prevalence of metabolic syndrome (MetS) in stable Chronic Obstructive Pulmonary Disease (COPD) patients and status of c-reactive protein among COPD patients with and without MetS visiting Tribhuvan University Teaching Hospital, Nepal. Eur Respir J. 2021 58: PA3640. DOI: 10.1183/13993003.congress-2021.PA3640 54. Karsanji U, Evans RA, Quint JK et al. Mortality associated with metabolic syndrome in people with COPD managed in primary care. ERJ Open Res. 2022; 8 (4): 00211-2022. DOI: 10.1183/23120541.00211-2022 55. Schane RE, Walter LC, Dinno A et al. Prevalence and risk factors for depressive symptoms in persons with chronic obstructive pulmonary disease. J Gen Intern Med. 2008; 23 (11): 1757–62. 56. Jennings JH, Digiovine B, Obeid D, Frank C. The association between depressive symptoms and acute exacerbations of COPD. Lung. 2009; 187 (2): 128–35. DOI: 10.1007/s00408-009-9135-9 57. Martínez-Gestoso S, García-Sanz MT, Carreira JM et al. Impact of anxiety and depression on the prognosis of copd exacerbations. BMC Pulm Med. 2022; 22, 169. DOI: 10.1186/s12890-022-01934-y 58. Mathews AM. The Functional and Psychosocial Consequences of COPD. Respir Care. 2023; 68 (7): 914–26. DOI: 10.4187/respcare. 10542 59. Harrison SL, Greening NJ, Williams JEA et al. Have we underestimated the efficacy of pulmonary rehabilitation in improving mood? Respir Med. 2012; 106 (6): 838–44. DOI: 10.1016/j.rmed.2011.12.003 60. Christiansen CF, Løkke А, Bregnballe V et al. COPD-Related Anxiety: A Systematic Review of Patient Perspectives. Int J Chron Obstruct Pulmon Dis. 2023; 18: 1031–46. 61. Rezaei SS, Rinner C, Ratajczak P et al. Use of beta‐blocker is associated with lower mortality in patients with coronary artery disease with or without COPD. Clin Respir J. 2018; 12: 2627–34. DOI: 10.1111/crj.12968 62. Janda S, Park K, FitzGerald JM et al. Statins in COPD: a systematic review. Chest. 2009; 136 (3): 734–43. DOI: 10.1378/chest.09-0194 63. Kang J, Lee R, Lee SW. Effects of gastroesophageal reflux disease treatment with proton pump inhibitors on the risk of acute exacerbation and pneumonia in patients with COPD. Respir Res. 2023; 24 (1): 75. DOI: 10.1186/s12931-023-02345-1